Navigation Links
Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice,with Transplant of Purified Donor Blood Stem Cells

autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.

About Cellerant

Cellerant Therapeutics is a commercial-stage company developing a portfolio of products and services focused on the regulation of the hematopoietic (blood-forming) system. Our products are based on adult hematopoietic stem and progenitor cells as both therapeutic agents and targets for drug discovery. Visit our website at http://www.cellerant.com.

Contact

Cellerant Therapeutics, Inc.
Bruce Cohen, 650-232-2122
or
MacDougall Biomedical Communications
Kari Watson, 508-647-0209
kari@macbiocom.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:11/7/2009)... Fla., Nov. 7 Patients reported C1...ective therapy in treating acute swelling attacks ...enetic disorder, according to data presented today...amp; Immunology (ACAAI) Annual Meeting. The result...ducted in parallel with the ongoing, prospective, ...
(Date:11/6/2009)...h., Nov. 6 SCOLR Pharma,...ts for the three and nine months ended September 3... President and CEO, said, "We continue to advance ...ofen formulation. Several potential partners have ... and external resources as they evaluate the poten...
(Date:11/6/2009)...ov. 6 Recession in domes... sales for Allied Healthcare Products in the first...2009. ,, Sales declines pushed Allied into a lo...was about $745,000, or negative 9 cents per share,...t $208,000, or 3 cents per share. ,, Sales fel...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 1Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 1Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 3Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 4Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 5Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 1Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 3
...y 10, 2007 /PRNewswire/ --,Pieris AG, a bio-pharma... class of targeted human protein therapeutics, tod...vel, effective products for,the potential treatmen... Anticalin(R) candidate, the Company reports that ...rget of action via,the lungs. , PRS-060 has been s...
...st for meeting with FDA, SEATTLE, July 11, 2007 /P...TI) announced today that interim results of,its ph...rone is,substituted for doxorubicin in standard CH...ive non-Hodgkin,s lymphoma (NHL), resulted,in esse...r,objective anti-tumor response (complete response...
Other Medicine Technology:Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 3Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 4Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 5
(Date:11/8/2009)... Passage of H.R. 3961 to Secure the Stability of M...ire/ -- Statement Attributable to: J. James Rohack..., (Logo: http://www.newscom.com/cgi-bin/prnh/...age of the House health reform bill, which will he...icians and calls for swift passage of H.R. 3961 to...
(Date:11/8/2009)...e Shows Who Sides With Working Families vs. Insura...wswire-USNewswire/ -- On the heels of an historic ...r a good, balanced health care reform bill, the Pe... state,s U.S. representatives voted on HR 3962, th...he legislation, which passed Saturday evening by a...
(Date:11/7/2009)... 7 Karen Ignagni, Presi...AHIP), released the following statement today on H...ongly support comprehensive health care reform, an...ing a complete overhaul of how health insurance is...ed coverage, elimination of pre-existing condition...
(Date:11/7/2009)... The American Medical As...ctor of Health at the Family Violence Prevention F...oday at its semi-annual policy-making meeting. Th...t honor the AMA House of Delegates bestows on a no...com/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms. J...
(Date:11/7/2009)... Members of the AMA are ...ncy resolution rescinding the AMA,s support of HR ...ey are responsible to their PATIENTS, not the lead...of Policy for the Association of American Physicia...on of other medical groups. ,, "If the AMA lea...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
...e "Extremely Affordable Health Innovations" Poste...al World Health Care Congress with support from Gr...ive organizations involved in developing or implem...eloped, or are in the process of developing, to th...
...EIGH, N.C., March 13 North Carolina students inte...re encouraged to attend the 2009 Optometry Career ...th Carolina and the N.C. State Education Assistanc...0:00 a.m. - 12:00 noon, Tuesday, March 24, 2009 in...
...CSF Medical Center has received a $125 million gif...specialty and cancer hospital complex at the UCSF ...his is the largest support to date for the $600 mi...t from other philanthropists, was made by Charles ...
...hanging physician behaviors forecast print news de... FALLS, N.J., March 13 , , Background : The...nsizing of many U.S. newspapers just a day after ...rk Times reports that three papers are ceasing t...
... HARBIN, China, March 13 /PRNewswire-Asia/ -- Chin...r "the Company") (Nasdaq: CSKI ), a leading full...-the-counter drugs in the,People,s Republic of Chi...e Conference in Shanghai and The World Money Show ...
...vista HPV HR: First FDA approved high-risk HPV tes...NA genotyping test approved by the FDA , , BEDFOR... Company) (Nasdaq: HOLX ), a leading women,s hea...Company,s premarket approval (PMA) applications fo...
Other Medicine News:Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 2Health News:Extremely affordable health innovations at World Health Care Congress, April 14-16, Washington 3Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 4Health News:Print Media Under Siege - Are Readers Disappearing? 2Health News:China Sky One Medical to Attend Two Conferences in March 2Health News:China Sky One Medical to Attend Two Conferences in March 3Health News:FDA Approves Two Hologic HPV Tests 2Health News:FDA Approves Two Hologic HPV Tests 3Health News:FDA Approves Two Hologic HPV Tests 4
Topcon OM-4 Ophthalmometer
...gital chip technology, the new IMAGEnet 2000 Super...res 3,072 x 2,048 pixels resolution and a 12-bit d...ovides exceptionally sharp and detailed images. It...facilitates instant diagnosis by allowing the inst...
Topcon TLS-FD trial lens set
AIT-15 instrument table
Medicine Products: